Featured Story BioCentury & Getty ImagesLeon Wang: Let China be China. The next phase in AZ’s China R&D strategy

Leon Wang believes that AstraZeneca has a chance to succeed at R&D in China because its global headquarters has learned to loosen the reins on its satellite premises. A multinational asking locals ...

Featured Story BioCentury & Getty ImagesThe writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority programs, and ...

Tools & Techniques BioCentury & Getty ImagesNew hepatic stellate cell subset drives liver fibrosis

A team including University of Edinburgh and Gilead researchers has used single-cell sequencing to zero in on a pathogenic subpopulation of hepatic stellate cells that could be targeted to treat liver ...

Tools & Techniques BioCentury & Getty ImagesEditas shows better gene editing using Cas9 alternative for sickle cell, thalassemia

Editas is using an alternative to Cas9 to develop a differentiated sickle cell and β thalassemia CRISPR gene therapy. Preclinical data presented Monday at ASH suggest that ex vivo gene editing could ...

Emerging Company Profile BioCentury & Getty ImagesZentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. ...

BioCentury Innovations ISSN 2377-3030